IPH 3102
This project uses retrospective studies which provide elements for proof of concept, and benefits from data acquired during clinical trials carried out between 1970 and 1980 with a TLR3 agonist, before the receptor had been identified.
This trial included 175 patients with breast cancer, testing a drug-candidate, poly(A:U) vs. placebo. Whereas the safety profile was good, this trial showed negative efficacy results. It was later proved that Poly(A:U) was a TLR3 agonist. Researchers at the Gustave Roussy Institute analyzed TLR3 expression on tumor slices from patients. The TLR3 receptor was strongly expressed in 18 patients (10% of the total population). It was observed, with a 20 year average hindsight after the treatment, that only those patients with TLR3 overexpression and treated with poly(A:U) had a survival advantage.
| Survival at 20 years | No treatment | Poly (A:U) treatment |
| Patients with TLR3- tumors (n=164) | 34% | 41% |
| Patients with TLR3+ tumors (n=18) | 20% | 88% |
Beyond breast cancer, the progress made by our research teams have demonstrated the sensitivity of melanoma cancer cells after treatment with alpha interferon, a drug currently being used for this type of cancer. This could be the first indication for which IPH 3102 could be developed.
| Cancer | % of Patients Expressing TLR3 |
| Breast cancer | 10% |
| Melanoma | > 80%* |
| Other cancers | Expression studies on-going |
* When treated previously with IFN-α
The program is in preclinical validation. The Company looks for a partner for further development.
More info? please donwload the following presentation of IPH 3102 program and/or see the section RNA targeting TLR.
